{"schema_version":"secwatch.filing_event.v1","accession":"0001549595-24-000038","form_type":"8-K","ticker":"NRIX","cik":"0001549595","company_name":"Nurix Therapeutics, Inc.","filed_at":"2024-03-11T23:59:59+00:00","discovered_at":"2026-05-14T18:03:24.570016+00:00","generated_at":"2026-06-04T23:49:25.510161+00:00","sec_items":["8.01","9.01"],"event_type":"regulatory","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"FDA lifts partial clinical hold on Nurix's NX-2127 Phase 1 trial; enrollment to resume","bullets":["FDA cleared new chirally controlled NX-2127 drug product; partial hold lifted March 11, 2024.","Enrollment reinitiated in Phase 1a/1b for relapsed/refractory B-cell malignancies.","Prioritizing aggressive NHL (DLBCL, MCL) where durable complete responses previously observed.","Patients currently enrolled and deriving benefit from prior process may continue treatment.","Company cites accelerated interest from ASH data and Science publication on BTK degrader programs."],"urls":{"canonical":"https://secwatch.observer/filing/0001549595-24-000038","json":"https://secwatch.observer/filing/0001549595-24-000038.json","markdown":"https://secwatch.observer/filing/0001549595-24-000038.md","text":"https://secwatch.observer/filing/0001549595-24-000038.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1549595/000154959524000038/0001549595-24-000038-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1549595/000154959524000038/nrix-20240311.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-04T23:49:25.510161+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}